You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
EIKANCE 0.01% is indicated as a treatment to slow the progression of myopia in children aged from 4 to 14 years. Atropine treatment may be initiated in children when myopia progresses greater than or equal to -1.0 D per year.
EIKANCE 0.01% eye drops are a clear, colourless solution packed in transparent polyethylene single-dose containers, which are sealed in aluminium laminated foil sachets
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
EIKANCE 0.01% is indicated as a treatment to slow the progression of myopia in children aged from 4 to 14 years. Atropine treatment may be initiated in children when myopia progresses greater than or equal to -1.0 D per year.
EIKANCE 0.01% eye drops are a clear, colourless solution packed in transparent polyethylene single-dose containers, which are sealed in aluminium laminated foil sachets
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
EIKANCE 0.01% is indicated as a treatment to slow the progression of myopia in children aged from 4 to 14 years. Atropine treatment may be initiated in children when myopia progresses greater than or equal to -1.0 D per year.
EIKANCE 0.01% eye drops are a clear, colourless solution packed in transparent polyethylene single-dose containers, which are sealed in aluminium laminated foil sachets
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
EIKANCE 0.01% is indicated as a treatment to slow the progression of myopia in children aged from 4 to 14 years. Atropine treatment may be initiated in children when myopia progresses greater than or equal to -1.0 D per year.
EIKANCE 0.01% eye drops are a clear, colourless solution packed in transparent polyethylene single-dose containers, which are sealed in aluminium laminated foil sachets
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
